Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement
- 30 April 2007
- journal article
- other
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 82 (4), 516-517
- https://doi.org/10.4065/82.4.516
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Maintenance therapy with thalidomide improves survival in patients with multiple myelomaBlood, 2006
- Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple MyelomaMayo Clinic Proceedings, 2006
- The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging systemEuropean Journal of Cancer, 2006
- Management of the adverse effects associated with intravenous bisphosphonatesAnnals of Oncology, 2006
- Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk FactorsJournal of Clinical Oncology, 2006
- Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk FactorsJournal of Clinical Oncology, 2005
- Osteonecrosis of the Jaw and BisphosphonatesThe New England Journal of Medicine, 2005
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003
- Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myelomaBritish Journal of Haematology, 2001
- Subgroup and cost‐benefit analysis of the Finnish multicentre trial of clodronate in multiple myelomaBritish Journal of Haematology, 1994